Weinberg Jeffrey M, Saini Ritu, Tutrone William D
Department of Dermatology, St. Luke's-Roosevelt Hospital Center, Beth Israel Medical Center, New York, New York, USA.
J Drugs Dermatol. 2002 Dec;1(3):303-10.
Over the last several years, a new generation of therapies for psoriasis has been in development. These biologic therapies target the activity of T lymphocytes and cytokines responsible for the inflammatory nature of this disease. In this review, we present an update on the progress of the four biologic agents in the forefront: infliximab, etanercept, efalizumab, and alefacept. The mechanism of each drug will be reviewed, as well as the most recent efficacy and safety data.
在过去几年中，新一代银屑病治疗方法一直在研发中。这些生物疗法针对的是导致该疾病炎症性质的T淋巴细胞和细胞因子的活性。在本综述中，我们介绍了处于前沿的四种生物制剂的进展情况：英夫利昔单抗、依那西普、依法利珠单抗和阿法赛特。将对每种药物的作用机制以及最新的疗效和安全性数据进行综述。
